Abstract: The present invention provides compositions and methods for treating skin conditions in a mammal. The compositions include, for example, Candelilla wax; Shea nut butter; Coconut oil; hempseed oil; Kukui nut oil; jojoba oil; sweet almond oil; Rosemary extract; Niaouli oil; and Vitamin E acetate. The skin conditions include, for example, a intertrigo, a skin fold, skin fold dermatitis, interdigital dermatitis, facial fold dermatitis, vulvar fold dermatitis, tail fold pyoderma and dermatitis, impetigo, Nasodigital hyperkeratosis, pruritus, pyoderma, pyotraumatic dermatitis, malodor, lesions, dermal rashes, dermal bacterial infection, dermal fungal infection, dermal weeping, hot spots, irritation, chaffing, itching, inflammation, or a combination thereof.

Abstract: The invention relates to a hyaluronic acid derivative and methods of preparation and modification of a hyaluronan derivative with an aldehydic group in the position (6) of the polysaccharide glucosamine part. The oxidation of the hyaluronic acid can be performed by means of Dess-Martin periodinane (DMP) agent. The prepared aldehyde can be used for binding amine, diamine, amino acid, peptide and other compounds containing an amino group, e.g. by means of the reductive amination with NaBH3CN in water or in a water-organic solvent system. When a diamine or compounds containing three or more amino groups are used, cross-linked hyaluronan derivatives can be prepared. Cross-linked derivatives can also be prepared by the reaction of the aldehyde with a hyaluronan substituted by an amino-alkyl group HA-alkyl-NH2.

Abstract: This invention provides a carrageenan mixture comprising about 60% to about 95% by weight of iota-carrageenans and about 5% to about 25% by weight of lambda-carrageenans, which is useful as an ingredient of a cosmetic formulation such as a fully natural hair styling gel being free from synthetic polymers.

Abstract: The present invention provides a composition, and a method of use thereof, for treating connective tissue damage in man and in animals, which comprises a therapeutically effective amount of chondroitin sulfate, N-acetyl D-glucosamine, and hyaluronan (hyaluronic acid). Particularly, the present invention provides a composition, and a method of use thereof, for treating connective tissue damage including, but not limited to, arthritic disease, osteoarthritis, rheumatoid arthritis, osterochondrosis dessicans, cartilage damage, joint injury, joint inflammation, joint synovitis, degenerative joint disease (DJD), post surgical DJD, traumatic injury, fracture, tendon damage, ligament damage, skeletal damage, musculoskeletal damage, fiber damage, adipose tissue damage, small intestine tissue damage, blood cell damage, and plasma damage. Compositions for delivery of the present invention include those for parenteral, oral, and transmucosal delivery and for direct surgical placement onto the affected tissues.

Abstract: Uses of depolymerized hyaluronan (e.g., prepared by sonicating high molecular weight hyaluronan such as naturally-occurring hyaluronan) or anti-Hyal-2 antibody in cancer treatment. Also described herein are methods for preparing depolymerized and crosslinked hyaluronan by sonication and the hyaluronan composition thus obtained.

Abstract: The present invention is related to a use for treating and preventing inflammation related disorder of a composition containing a drug and hyaluronic acid (HA) or HA mixture, whereas the HA or the HA mixture as a delivery vehicle can be a formulation including at least two HAs having different average molecular weights. The composition has been demonstrated to be capable of reducing the therapeutic dose of a drug on the treatment and prevention of inflammation related disorders is acute inflammatory disease, chronic obstructed pulmonary disease, coeliac disease, conjunctivitis, otitis, allergic rhinitis, gingivitis, aphthous ulcer, bronchitis, gastroesophageal reflux disease (GERD), esophagitis, gastritis, enteritis, peptic ulcer, inflammatory bowel disease (IBD), Crohn's Disease, irritable bowel syndrome (IBS), intestinal inflammation or allergy, urethritis, cystitis, vaginitis, proctitis, eosinophilic gastroenteritis, or rheumatoid arthritis.

Abstract: A Chinese herbal medical composition in the form of jelly, wherein a Chinese herbal medicine is contained in a base containing at least one substance selected from the group consisting of carrageenan, carob bean gum and xanthan gum and not containing phosphate buffer. The Chinese herbal medical composition hardly causes syneresis, is superior in the preservative stability, is broadly applicable to a Chinese herbal medicine and is orally taken without taking care of the bitter of a Chinese herbal medicine.

Abstract: Preparations of polysaccharides lacking substantial anticoagulant activity are provided herein. Methods of making and using such preparations are provided.

Abstract: A process for preparing a crosslinked gel of at least one polymer or one of its salts, including a) providing an aqueous medium containing at least one polymer, b) forming a homogenous gel from the medium from step a), c) bringing the gel obtained in step b) into contact with an effective amount of at least one crosslinking agent; d) crosslinking the mixture formed in step c); and e) recovering the crosslinked hydrogel, wherein at least steps a) to d) are carried out within a hermetic cavity delimited at least partially by a deformable wall, the mixture present in the cavity being exposed, in step d), to conditions conducive to crosslinking.

Abstract: The present disclosure provides a method for suppressing a proinflammatory response by administering a composition comprising peptides selected from a casein hydrolysate. Such a composition may reduce the levels of proinflammatory cytokines and may be a treatment for inflammatory disease, especially type 1 diabetes. Preferably, the hydrolysate consists of peptides with a molecular weight of more than 500 Da.

Abstract: The disclosure provides hyaluronic acid (HA) gel formulations and methods for treating the appearance of the skin. The formulations hyaluronic acid and at least one additional ingredient. Methods for treating lines, wrinkles, fibroblast depletions, and scars with the disclosed composition are provided as well.

Abstract: The present invention relates to a methods and compositions for the treatment of and management of symptoms for thyroid eye disease. The methods include administering to a patient having thyroid eye disease an agent that interferes with hyaluronan synthesis in an amount that is effective to inhibit hyaluronan synthesis in a retro-ocular space. The pharmaceutical compositions hat includes a carrier suitable for ophthalmic delivery and an agent that interferes with hyaluronan synthesis. Combination therapies are also disclosed.

Abstract: The present invention relates to a glucan having a weight average molar mass of 15,000 to 50,000 g/mol on a single chain basis and a weight average molar mass in aqueous solution on an aggregate basis of 4 to 20×105 g/mol and existing in gel form in aqueous solution at a concentration ?1% at 25° C. and neutral pH and having a melting temperature (gel to sol) of 35 to 60° C. when the glucan is dissolved in water at a concentration of 2%, methods for the production thereof, medical uses thereof, physical supports having the glucan applied thereto or impregnated thereon and in vitro methods of proliferation of skin cells which comprise contacting a population of skin cells with the glucan.

Abstract: Provided herein are insoluble particles that include polypeptides. The polypeptides may have immunogenicity that is greater than the immunogenicity of the same polypeptides when they are not present in the particle. The polypeptides may be soluble before incorporation into the particles and insoluble after incorporation into the particles. The particles may include lipopolysaccharide, wherein the lipopolysaccharide is insoluble. The particles may include a carrier. In one embodiment, a carrier is present at no greater than 0.001 mg carrier/mg particles. In one embodiment, a carrier is present at a ratio of carrier to polypeptide (weight:weight) of no greater than 0.05:1. In one embodiment, a carrier is not detectable in the particles.

Abstract: The use is described of a conjugate between hyaluronic acid or a derivative thereof and antitumoral drugs for the preparation of pharmaceutical compositions for the topical treatment of hyperproliferative skin diseases.

Abstract: A novel influenza C virus with only low homology to any influenza C virus previously characterized. Challenge studies show that the virus can infect pigs and be transmitted between pigs. Additionally, influenza C is commonly thought of as a human pathogen and serological studies have been performed, looking at the incidence of antibodies against this virus in both pigs and humans. Approximately 10% of pigs and 30% of humans have antibodies to this virus. Additional experimental data show that the virus can infect and transmit in ferrets (a surrogate for human infection studies). In a third aspect, the present invention is the partial genome of this novel influenza C virus. In another aspect, the present invention is a method of detection in animals of this novel influenza C virus.

Abstract: Contemplated compositions and methods are drawn to use of various boron-containing compounds to temporarily and transiently increase endogenous blood calcitriol concentration. The boron-containing compound is preferably a carbohydrate-boron complex having sufficient stability to achieve measurable quantities of the complex in blood upon oral administration of the complex.

Abstract: This invention relates to a preparation comprising N-acetyl-lactosamine and/or an oligosaccharide containing N-acetyl-lactosamine and a probiotic Lactobacillus sp. The invention extends to nutritional compositions comprising said preparation and to the use of the preparation in the prevention and treatment of pathogenic infections of the gastro-intestinal and upper respiratory tracts.

Abstract: A mixed metal compound for pharmaceutical use is free from aluminum and has a phosphate binding capacity of at least 30%, by weight of the total weight of phosphate present, over a pH range of from 2-8. The compound is especially useful for treatment of hyperphosphataemia. The metals are preferably iron (III) and at least one of calcium, magnesium, lanthanum and cerium. A metal sulphate for pharmaceutical use is selected from at least one of calcium, lanthanum and cerium sulphate compounds and has a phosphate binding capacity of at least 30% by weight of the total phosphate present, over a pH range from 2-8.

Abstract: Ophthalmic compositions including lubricant agent, deturgescent agent, glycosaminoglycan, and water are used to preserve tissue in vitro; for example, ocular tissue, especially a cornea, thereby facilitating subsequent transplant, especially of a complete cornea. Preferably, the ophthalmic composition and tissue are stored at about 0° C. to about 40° C. The ophthalmic solution may be replaced on either a continuous basis or batch exchanged. The volume of ophthalmic solution per individual cornea being preserved would be from about 50 ml to about 500 ml.

Abstract: A disinfectant, sanitizer, germicide, mildicide, virucide, deodorizer, decontaminator and cleaning formulation for cleaning porous and non-porous materials in hospitals, institutions, farms, hotels, cruise ships, homes, schools and other environments is provided. The cleaning formulation comprises a first component including an aqueous alkaline solution containing a surfactant, a triamine, and a quaternary halide and a second component containing an aqueous stabilized hydrogen peroxide solution. The formulation is activated by combining and mixing the two components. The activated formulation can be applied to a surface to be cleaned and/or sanitized with standard techniques. The two components can also be provided as a disinfectant/sanitizer kit.

Abstract: The invention discloses the discovery that a pharmaceutical composition containing complex carbohydrates with or without natural or synthetic essential oils can work effectively as a topical, oral or mucosal pharmaceutical composition. Such pharmaceutical compositions reduce inflammation, assist in wound healing, protect against bruising, relieve itching, relieve pain and swelling and treat topical bacterial infections such as acne and decubitus ulcers and prevent and treat numerous other conditions and diseases. Such pharmaceutical compositions can be administered to mammals including humans. Also included in this invention are methods to deliver topically applied macromolecules into the tissue of mammals and methods of blocking the adhesion, metastatic and coronary cascades.

Abstract: The present invention provides a crosslinked hyaluronic acid composition including self-crosslinking hyaluronic acid particles having an equilibrium swelling capacity of 3-fold to 10-fold, and an aqueous solvent, wherein a dry weight of the self-crosslinking hyaluronic acid particles based on the total volume of the crosslinked hyaluronic acid composition is 3 w/v % to 8 w/v %. The crosslinked hyaluronic acid composition of the invention uses self-crosslinking hyaluronic acid particles of which the equilibrium swelling capacity is within the above predetermined range. Accordingly, the viscosity does not sharply increase even if the concentration thereof is increased. Therefore, if the crosslinked hyaluronic acid composition is applied to an injection, it is possible to obtain a sufficient curative effect on knee osteoarthritis even with a small frequency of administration.

Abstract: This invention provides a method for introducing substances into cells comprising contacting a composition comprising orally administered beta-glucan with said cells. This invention also provides a method for introducing substances into a subject comprising administering to the subject an effective amount of the above compositions. The substance which could be delivered orally includes but is not limited to peptides, proteins, RNAs, DNAs, chemotherapeutic agents, biologically active agents, plasmids, and other small molecules and compounds. Finally, this invention provides a composition comprising orally administered beta-glucan capable of enhancing efficacy of IgM and different uses of the said composition.

Abstract: The present invention relates to an Echinacea formulation which includes an alkylamide fraction comprising a 2-ene alkylamide fraction and a 2,4-diene alkylamide fraction and the weight ratio of the 2-ene alkylamide fraction to the 2,4-diene alkylamide fraction is between about 1:15 to about 2:1.

Abstract: Methods and compositions for reducing fibrosis and cirrhosis are provided in which an effective dose of an admixture of a polysaccharide compound and, for example, a compound selected from the group consisting of antibodies specific to intracellular or cell-surface: (i) beta-PDGF receptors; (ii) synaptophysin; (iii) zvegf3; (iv) CCR1 receptors; (v) connective tissue growth factor; (vi) alpha 1-smooth muscle actin; (vii) matrix metalloproteinases MMP 2 and MMP9; (viii) matrix metalloproteinase inhibitors TIMP1 and TMP2; (ix) integrins; (x) TFG-?1; (xi) endothelin receptor antagonists; and (xii) collagen synthesis and degradation modulating compounds; (xiii) actin synthesis and degradation modulating compounds; and (xiv) tyrosine kinases is administered to an animal in order to treat fibrosis.

Abstract: Nutritionally enhanced nutraceutical Hydrophilic and Lipophilic Rice Bran Fractions from rice bran are provided, as well as a method of using the same to reduce Insulin Resistance in animals, especially humans with pre-diabetes and Type 2 diabetes or others with symptoms of Metabolic Syndrome. Provided in various example embodiments are mixtures of elevated levels of nutraceutical compounds, including but not limited to gamma-oryzanol, inositol, ferulic acid, tocotrienols and phytosterols and pharmaceutical and nutritional compositions thereof. Steps are provided including evaluating insulin resistance parameters, initiating therapy including providing therapeutic amounts of Hydrophilic and Lipophilic Rice Bran Fractions from rice bran to treat pre-diabetes and Type 2 diabetes or others with symptoms of Metabolic Syndrome, managing compliance with the therapy, and monitoring and reevaluating the therapy.

Abstract: A pharmaceutical preparation for treating connective tissue damage in man and in animals, comprising a therapeutically effective amount of a glycosaminoglycan composition comprising chondroitin sulfate, N-acetyl D-glucosamine, and hyaluronan, in combination with isolated stem cells. Methods of use and kits containing the glycosaminoglycan composition and materials for isolating stem cells and for treating connective tissue damage and repair of cartilage in man and in animals are also provided.

Abstract: A method of treatment of liver diseases and comorbid diseases is disclosed wherein an oral dose of lipids in an amount effective to trigger the release of cholecystokinin (CCK) into the duodenum to generate a major release of bile phospholipids from remodeled stores of triglycerides (TAG) in the liver, is administered to a patient in need thereof, thereby causing the formation of sequestered and aggregated mixed micelles and vesicles (SAMMVs) in the intestines of the patient which are then eliminated via the bowels of the patient.

Abstract: A pharmaceutical composition including an alkaline metal alginate, an alkaline salt, and less than 10% by weight based on the weight of the alkaline metal alginate of a calcium salt. The pharmaceutical composition is intended for the treatment or prophylaxis of dyspepsia in a mammal.

Abstract: Compositions containing tocotrienol, non-tocotrienol lipids and surface active agents; compositions containing particles having a statin and a tocotrienol wherein the particle size is less than 1000 nm; and microemulsions containing a statin and a tocotrienol are disclosed. Methods relating to the creation of such compositions and the use of such compositions are further disclosed.

Abstract: The invention concerns an in vitro method for diagnosing Crohn's disease, or for determining predisposition in a person to develop Crohn's disease, by detecting an overexpression of the CD66c receptor in subjects suffering from said disease or at risk. The invention also concerns preventive or curative treatment of Crohn's disease.

Abstract: The present invention relates to compositions comprising ethyleneoxide butyleneoxide and a galactomannan such as guar. The compositions are particularly well suited for ophthalmic applications such as contact lens disinfection and rewetting. Methods for the treatment of dry eye using the compositions of the present invention are also contemplated.

Abstract: Infection of pathogens is controlled by inducing disease resistance with a method of treating a plant with a composition of an acidic heat-treated solution of microorganisms.

Abstract: The present invention relates to compositions containing probiotic bacteria and uronic acid oligosaccharides. The compositions can suitably be used as infant nutrition and advantageously reduce the incidence of infection.

Abstract: Flowable compositions and methods are provided for delivering a therapeutic agent at or near a target tissue site beneath the skin of a patient, the flowable composition comprising (i) a solvent and (ii) an effective amount of the therapeutic agent, the flowable composition being capable of hardening to form a drug depot at a physiological temperature or as solvent contacts bodily fluid at or near the target tissue site, wherein the drug depot is capable of releasing the therapeutic agent over a period of at least one day and the target tissue site comprises at least one muscle, ligament, tendon, cartilage, spinal disc, spinal foraminal space near the spinal nerve root, facet or synovial joint, or spinal canal.

Abstract: The invention provides a use of panthenol or dexpanthenol in the prevention and/or treatment of contact lens papillary conjunctivitis in a subject. A contact lens care solution containing 0.001 to 10% by dry weight dexpanthenol is also provided.

Abstract: Described are oligosaccharides having a protecting group at two, a plurality, a majority of, or each position in the oligosaccharide which is amenable to derivatization. Collections, libraries and methods of making and using such oligosaccharides are also described.

Abstract: A method of treating a vaginal or vulvar vestibule mucosa disorder involves administering a composition comprising a hyaluronic acid or a salt thereof to the vagina, vulvar or vulvar vestibule of an individual that has the disorder to treat the disorder. The method may be used to treat vaginal atrophy or vulvar vestibulitis syndrome, among other vulvovaginal mucosa disorders.

Abstract: A sterile injectable aqueous formulation in the form of a gel is made up of hyaluronic acid (or one of the salts thereof) with or without other natural polysaccharide(s) and one or more polyols. The formulation is of intra-articular application in the treatment of joint degeneration, in some cases having a rheology similar to that of synovial liquid and always with an elevated resistance to degradation due to a synergistic action between the hyaluronic acid and the polyols.

Abstract: A composition for external use on skin that can be spread evenly on the skin, does not produce a liquid residue as a result of temperature change, and can suppress a feeling of sliminess of xanthan gum is provided. There are provided a composition for external use on skin containing 0.1% by mass to 10% by mass of a component (A) (a water-soluble polymer obtained by mixing agar with xanthan gum) and 30% by mass or more of a component (D) (water); the composition for external use on skin containing 0.5% by mass to 40% by mass of a divalent polyol as a component (B); the composition for external use on skin according to any one of the above compositions, which contains moisturizers as a component (C); and the composition for external use on skin according to any one of the above compositions, which contains oil as a component (E).

Abstract: Hydrogel compositions including phenylephirne and methods of treating soft tissue conditons using such hydrogel compositions, are provided.

Abstract: The present invention relates to a disorder of the lower urinary tract, and in particular, reducing the symptoms (including treatment) of interstitial cystitis in vivo. In a preferred embodiment, the present invention relates to treatment formulations and methods for reducing interstitial cystitis in patients via administration of a therapeutically effective concentration of PRG4.

Abstract: The present invention is directed to methods of producing conjugates of A? peptide immunogens with protein/polypeptide carrier molecules, which are useful as immunogens, wherein peptide immunogens are conjugated to protein carriers via activated functional groups on amino acid residues of the carrier or of the optionally attached linker molecule, and wherein any unconjugated reactive functional groups on amino acid residues are inactivated via capping, thus retaining the immunological functionality of the carrier molecule, but reducing the propensity for undesirable reactions that could render the conjugate less safe or effective. Furthermore, the invention also relates to such immunogenic products and immunogenic compositions containing such immunogenic products made by such methods.

Abstract: This invention is directed to derivatives of piperidine-2,6-dione, or their organic or inorganic salts thereof, a methods of synthesis of these derivatives, and their application as active pharmaceutical ingredient as inhibitors of TNF? releasing in cells, the derivative of piperidine-2,6-dione being of the general formula (I): wherein n represents 1, 2, 3, 4, 5 or 6; R1 represents from one to four of the same or different substituents selected from F, Cl, Br, C1-4 alkyl, OH, OC1-4 alkyl, NO2, NHC(O)C1-4 alkyl, NH2, NH(C1-4 alkyl), N(C1-4 alkyl)2; R2 represents OR3, NR3R4, N(R3)COR4, O2CR5; R3 and R4 represent independently and at each occurrence H or C1-4 alkyl; R5 represents CHR6NR7R8, CHR6NR9C(O)CHR10NR7R8, a heterocycle W or CHR6NR9C(O)W; R6, R9, R10 represent independently and at each occurrence H, or C1-4 alkyl; R7 and R8 represent independently and at each occurrence H, C1-4 alkyl, or R7 and R8 taken together represent 1,3-propylene, 1,4-butylene, 1,5-pentylene, or 1,6-hexylene; W represents four-m

Abstract: Hemostatic devices for promoting blood clotting can include a substrate (e.g., gauze, textile, sponge, sponge matrix, one or more fibers, etc.), a hemostatic material disposed thereon such as kaolin clay, and a binder material such as crosslinked calcium alginate with a high guluronate monomer molar percentage disposed on the substrate to substantially retain the hemostatic material material. When the device is used to treat a bleeding wound, at least a portion of the clay material comes into contact with blood to accelerate clotting. Moreover, when exposed to blood, the binder has low solubility and retains a majority of the clay material on the gauze. A bandage that can be applied to a bleeding wound to promote blood clotting includes a flexible substrate and a gauze substrate mounted thereon.

Abstract: This application provides methods and compositions for the treatment of cancer. The application provides compositions including hyaluronic acid and a chemotherapeutic agent such as irinotecan that are useful in the treatment of cancer.

Abstract: A process for the crosslinking of at least one polymer selected from polysaccharides and derivatives thereof, which is carried out in an aqueous solvent by the action of an effective and non-excessive amount of at least one crosslinking agent, characterized in that it is carried out on a mixture containing at least one low-molecular weight polymer and at least one high-molecular weight polymer. A process for the preparation of an injectable monophase hydrogel of at least one crosslinked polymer selected from polysaccharides and derivatives thereof. Crosslinked polymers and injectable monophase hydrogels respectively obtainable by each of said processes.

Abstract: An agent for eliminating a drug and an accelerator for eliminating a drug which comprise hyaluronic acid or a salt thereof.

Abstract: Fractions extracted from wheat seeds germinated and macerated in water having a molecular weight comprised between 3 and 30 K Daltons are described.